Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CELC

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Celcuity LLC

CELC
Current price
13.59 USD -0.16 USD (-1.16%)
Last closed 13.75 USD
ISIN US15102K1007
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 520 663 008 USD
Yield for 12 month -25.62 %
1Y
3Y
5Y
10Y
15Y
CELC
21.11.2021 - 28.11.2021

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota. Address: 16305 36th Avenue North, Minneapolis, MN, United States, 55446

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.71 USD

P/E Ratio

Dividend Yield

Financials CELC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-142 772 USD

Current Quarter

Last Quarter

EBITDA -126 770 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -39.04 %
PEG Ratio
Return On Equity TTM -115.39 %
Wall Street Target Price 28.71 USD
Revenue TTM
Book Value 2.29 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -3.05 USD
Diluted Eps TTM -3.05 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -7.80
Price Book MRQ 6.01

Technical Indicators CELC

For 52 Weeks

7.58 USD 19.77 USD
50 Day MA 11.75 USD
Shares Short Prior Month 2 444 767
200 Day MA 12.25 USD
Short Ratio 17.20
Shares Short 2 413 909
Short Percent 7.36 %